Business Wire07.24.19
Outset Medical, a commercial-stage company delivering first-of-its-kind technology into the growing global dialysis market, has appointed Rebecca Chambers as chief financial officer. Chambers joins Outset from Illumina, a developer of DNA sequencing technology.
Over the course of her career at Illumina, Chambers led numerous financial functions including treasury, clinical financial planning and analysis and investor relations (IR). Prior to Illumina, she led IR and corporate communications at Myriad Genetics, a molecular diagnostics company in Salt Lake City, Utah, as well as various roles at Life Technologies, now part of Thermo Fisher Scientific, Bank of America Merrill Lynch, and Millennium Pharmaceuticals, now Takeda Pharmaceuticals.
“Rebecca’s deep capital markets expertise and growth-company track record is ideally suited to our stage of commercial expansion,” said Leslie Trigg, Outset’s CEO. “We recognized in Rebecca a best-in-class ability to build a strong financial foundation and effective, transparent relationships with the investment community. We are thrilled to welcome her to the leadership team.”
“I am honored to be a part of Outset at this time in its growth trajectory. It is a rare opportunity to join a team passionate about transforming a stagnant, but rapidly growing market with a huge unmet patient need,” said Chambers. “The Tablo Hemodialysis System has the potential to fundamentally change the way dialysis is delivered and improve the lives of patients and providers, while also driving significant cost efficiencies.”
Although more than 91 million dialysis treatments take place in the United States each year at an estimated annual cost of $65 billion, little meaningful technology or service model innovation has been introduced in decades. Tablo was specifically designed to reduce the cost and complexity of dialysis, while improving the experience for patients and providers. With real-time water purification and dialysis fluid production integrated in a single, compact system, Tablo functions like a dialysis clinic on wheels. Requiring just an electrical outlet and tap water to operate, Tablo frees providers from having to rely on expensive clinic infrastructure, enabling on-demand, cost-effective dialysis in a range of environments. Tablo was designed to look and feel like an intuitive consumer product, keeping end-user simplicity in mind. Wireless data, sensor-based automation, and an animated touchscreen aim to make Tablo easy to learn and use for healthcare professionals and patients alike.
Outset Medical is dedicated to delivering patient-centered dialysis through service model and technology innovation aimed at reducing cost and transforming the patient care experience. Outset’s Tablo System is U.S. Food and Drug Administration-cleared and CE-marked for use in acute and chronic care settings. In addition to its acute and chronic care commercial expansion, the company is conducting a clinical trial exploring the use of Tablo for home dialysis.
Over the course of her career at Illumina, Chambers led numerous financial functions including treasury, clinical financial planning and analysis and investor relations (IR). Prior to Illumina, she led IR and corporate communications at Myriad Genetics, a molecular diagnostics company in Salt Lake City, Utah, as well as various roles at Life Technologies, now part of Thermo Fisher Scientific, Bank of America Merrill Lynch, and Millennium Pharmaceuticals, now Takeda Pharmaceuticals.
“Rebecca’s deep capital markets expertise and growth-company track record is ideally suited to our stage of commercial expansion,” said Leslie Trigg, Outset’s CEO. “We recognized in Rebecca a best-in-class ability to build a strong financial foundation and effective, transparent relationships with the investment community. We are thrilled to welcome her to the leadership team.”
“I am honored to be a part of Outset at this time in its growth trajectory. It is a rare opportunity to join a team passionate about transforming a stagnant, but rapidly growing market with a huge unmet patient need,” said Chambers. “The Tablo Hemodialysis System has the potential to fundamentally change the way dialysis is delivered and improve the lives of patients and providers, while also driving significant cost efficiencies.”
Although more than 91 million dialysis treatments take place in the United States each year at an estimated annual cost of $65 billion, little meaningful technology or service model innovation has been introduced in decades. Tablo was specifically designed to reduce the cost and complexity of dialysis, while improving the experience for patients and providers. With real-time water purification and dialysis fluid production integrated in a single, compact system, Tablo functions like a dialysis clinic on wheels. Requiring just an electrical outlet and tap water to operate, Tablo frees providers from having to rely on expensive clinic infrastructure, enabling on-demand, cost-effective dialysis in a range of environments. Tablo was designed to look and feel like an intuitive consumer product, keeping end-user simplicity in mind. Wireless data, sensor-based automation, and an animated touchscreen aim to make Tablo easy to learn and use for healthcare professionals and patients alike.
Outset Medical is dedicated to delivering patient-centered dialysis through service model and technology innovation aimed at reducing cost and transforming the patient care experience. Outset’s Tablo System is U.S. Food and Drug Administration-cleared and CE-marked for use in acute and chronic care settings. In addition to its acute and chronic care commercial expansion, the company is conducting a clinical trial exploring the use of Tablo for home dialysis.
